COVID-19 pneumonia who are recieving favipiravir treatment

Ozturk, S.; Colak, O.; Kavas, S.; Engin, D. O.; Tahtasakal, S. D.; Ari, D. E.; Demiroluk, O.; Ozdemir, B.; Cetinkaya, B. M.; Eker, M. K.; Dogan, I. A.; Vahaboglu, H.; Agalar, C.

Introduction: There is no known specific treatment for Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Our retrospective study evaluates the effectiveness of steroid treatment and the factors affecting treatment in patients with severe Coronavirus disease-2019 (COVID-19) pneumonia that received favipiravir treatment. Materials and Methods: This study included patients older than 18 years with severe COVID-19 pneumonia who received favipiravir treatment in a training and research hospital between March 1 and May 31, 2020. It retrospectively evaluated respiratory rate >30/min and/or severe respiratory distress and oxygen saturation <90 and typical thoracic computerized tomography findings: Bilateral lobular, peripheral lesions, and the presence of ground-glass opacities were determined as the criteria for severe pneumonia. For 82 cases of SARS-CoV-2 polymerase chain reaction positive, age, gender, symptoms, comorbidities, steroid use, and mortality rates were examined.